†rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

BUSINESS DESCRIPTIONMAIN PRODUCTSPantoloc ® /Zurcale ®Pantoprazole is a Proton Pump Inhibitor for the treatment of patients with acidrelated diseases, e.g. peptic ulcers. The product produces very fast symptomaticrelief and optimal healing rates. It offers several advantages, like very smalltablets that are easy to swallow, fast pain relief and lack of interaction with coadministereddrugs.The product is introduced in all of Nycomed’s major markets, but under the differenttrademarks Pantoloc ® , Pantozol ® and Zurcal ® / Zurcale ® . The product is copromotedwith Byk Nederland under the Pantozol ® trademark in Holland. InBelgium, Austria, Switzerland and Greece, the product is co-marketed underNycomed's trademark Zurcal ® / Zurcale ® . In Denmark and Sweden, the productis launched on an exclusive basis under Byk Gulden’s international brand name,Pantoloc ® .Sales 1999Sales 2000DKK 147 millionDKK 200 million(+35.9% from 1999)–25–